Kirtland Hills Capital Management LLC Acquires New Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Kirtland Hills Capital Management acquired 1,759 Thermo Fisher Scientific shares worth approximately $882,000 in the second quarter. Institutional investors and hedge funds collectively own 89.23% of TMO.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $619.41, although recent targets and ratings have varied.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in adjusted EPS and $11.99 billion in revenue, while revenue rose 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

Kirtland Hills Capital Management LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,759 shares of the medical research company's stock, valued at approximately $882,000.

Several other hedge funds also recently modified their holdings of TMO. Legacy Wealth Managment LLC ID lifted its holdings in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after buying an additional 22 shares during the period. Kilter Group LLC bought a new stake in Thermo Fisher Scientific in the second quarter worth about $25,000. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $26,000. High Note Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and dropped their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Piper Sandler increased their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research report on Monday, July 27th. Jefferies Financial Group restated a "buy" rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 4,608 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 63,493 shares of company stock worth $37,657,681. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 0.2%

TMO stock opened at $629.02 on Friday. The company's 50 day simple moving average is $542.53 and its 200-day simple moving average is $509.70. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $232.58 billion, a P/E ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same period in the previous year, the company posted $4.28 EPS. The company's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source